NO841613L - Fremgangsmaate for produksjon av en human-insulinliknende vekstfaktor, samt dna-sammensetning for fremgangsmaatens utfoerelse - Google Patents

Fremgangsmaate for produksjon av en human-insulinliknende vekstfaktor, samt dna-sammensetning for fremgangsmaatens utfoerelse

Info

Publication number
NO841613L
NO841613L NO84841613A NO841613A NO841613L NO 841613 L NO841613 L NO 841613L NO 84841613 A NO84841613 A NO 84841613A NO 841613 A NO841613 A NO 841613A NO 841613 L NO841613 L NO 841613L
Authority
NO
Norway
Prior art keywords
igf
host
procedure
human
growth factor
Prior art date
Application number
NO84841613A
Other languages
English (en)
Other versions
NO174302B (no
NO174302C (no
Inventor
Philip J Barr
James P Merryweather
Guy Mullenbach
Mickey S Urdea
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO841613L publication Critical patent/NO841613L/no
Publication of NO174302B publication Critical patent/NO174302B/no
Publication of NO174302C publication Critical patent/NO174302C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
NO841613A 1983-04-25 1984-04-24 Fremgangsmåte for produksjon av en human-insulin-lignende vekstfaktor NO174302C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48795083A 1983-04-25 1983-04-25

Publications (3)

Publication Number Publication Date
NO841613L true NO841613L (no) 1984-10-26
NO174302B NO174302B (no) 1994-01-03
NO174302C NO174302C (no) 1994-04-13

Family

ID=23937779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO841613A NO174302C (no) 1983-04-25 1984-04-24 Fremgangsmåte for produksjon av en human-insulin-lignende vekstfaktor

Country Status (17)

Country Link
US (1) US6642029B1 (no)
EP (2) EP0123228B1 (no)
JP (2) JP2548105B2 (no)
AT (2) ATE220101T1 (no)
AU (1) AU576757B2 (no)
DE (2) DE3486216T2 (no)
DK (1) DK204584A (no)
ES (1) ES531855A0 (no)
FI (1) FI87799C (no)
HK (1) HK65594A (no)
HU (1) HU204565B (no)
IE (2) IE60228B1 (no)
IL (1) IL71634A (no)
NO (1) NO174302C (no)
NZ (1) NZ207842A (no)
PT (1) PT78484B (no)
ZA (1) ZA842982B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US7198919B1 (en) 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
JPS60501989A (ja) * 1983-08-10 1985-11-21 アムジエン インシュリン様成長因子の微生物発現
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
JP2549504B2 (ja) * 1984-12-21 1996-10-30 ア−ス製薬株式会社 Ｄｎａ塩基配列、ポリペプチド分泌発現ベクター及び形質転換微生物
US5242811A (en) * 1985-03-26 1993-09-07 Biogen, Inc. Production of human somatomedin C
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5342921A (en) * 1985-03-28 1994-08-30 Chiron Corporation Superoxide dismutase fusion polypeptides for expression of mammalian proteins
ATE63757T1 (de) * 1985-03-28 1991-06-15 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
ATE67243T1 (de) * 1985-10-21 1991-09-15 Fujisawa Pharmaceutical Co Verfahren zur herstellung von insulinaehnlichem wachstumsfaktor i (igf-i) und plasmid zu dessen herstellung.
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
EP0234871A3 (en) * 1986-02-28 1988-10-12 Merck & Co. Inc. Regulatable expression of recombinant proteins in yeast
EP0234862A3 (en) * 1986-02-28 1988-10-05 Merck & Co. Inc. Expression of recombinant proteins in yeast
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトｐｓｔｉの製造法
DE3726655A1 (de) * 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
GB8723660D0 (en) * 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
DE68905203T2 (de) * 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
JPH06500470A (ja) * 1990-09-04 1994-01-20 メルク　エンド　カンパニー　インコーポレーテッド メチロトローフ酵母細胞におけるインスリン様成長因子の産生
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
DE69232666T2 (de) * 1991-04-01 2003-03-20 Merck & Co., Inc. Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
TW267102B (no) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
JPH10504971A (ja) * 1994-09-08 1998-05-19 カイロン コーポレイション インスリン様増殖因子の改善された生産方法
PT1486565E (pt) 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
DE60005806T2 (de) 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
US6790641B2 (en) 2002-05-01 2004-09-14 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
CN102861321A (zh) 2003-09-12 2013-01-09 特西卡股份有限公司 胰岛素样生长因子-1(igf-1)缺陷的治疗方法
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
MX2009001691A (es) 2006-08-31 2009-02-25 Hoffmann La Roche Metodo para produccion del factor de crecimiento i tipo insulina.
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
PE20120415A1 (es) 2008-12-12 2012-05-09 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US20210008172A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411994A (en) * 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4443539A (en) 1980-02-05 1984-04-17 The Upjohn Company Process for preparing bovine growth hormone
CA1200773A (en) * 1980-02-29 1986-02-18 William J. Rutter Expression linkers
US4350764A (en) * 1980-03-10 1982-09-21 The Regents Of The University Of California Microbiological synthesis of beta endorphin
AU545912B2 (en) * 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
DE3382547D1 (de) * 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
AU2722184A (en) * 1983-04-25 1984-11-01 Genentech Inc. Use of alpha sequences in yeast expression systems
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0193112A3 (en) 1985-02-22 1987-02-25 The Trustees Of Columbia University In The City Of New York Cdna encoding mammalian insulin-like growth factor ii
US5084384A (en) * 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
JPH06500470A (ja) * 1990-09-04 1994-01-20 メルク　エンド　カンパニー　インコーポレーテッド メチロトローフ酵母細胞におけるインスリン様成長因子の産生
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
EP1365028B1 (en) 1996-12-13 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Method for expression of PDGF or IGF proteins in yeast

Also Published As

Publication number Publication date
FI841524A (fi) 1984-10-26
IE60228B1 (en) 1994-06-15
IE840975L (en) 1984-10-25
AU2723384A (en) 1984-11-01
HK65594A (en) 1994-07-15
HUT34236A (en) 1985-02-28
HU204565B (en) 1992-01-28
EP0123228A2 (en) 1984-10-31
AU576757B2 (en) 1988-09-08
DE3486216D1 (de) 1993-11-04
IL71634A0 (en) 1984-07-31
FI87799B (fi) 1992-11-13
ATE95236T1 (de) 1993-10-15
ES8505412A1 (es) 1985-05-16
NZ207842A (en) 1988-02-12
NO174302B (no) 1994-01-03
PT78484A (fr) 1984-05-01
ZA842982B (en) 1984-11-28
ATE220101T1 (de) 2002-07-15
IE940140L (en) 1984-10-25
JP2548105B2 (ja) 1996-10-30
EP0123228B1 (en) 1993-09-29
JPS59205997A (ja) 1984-11-21
IL71634A (en) 1992-09-06
DE3486491D1 (de) 2002-08-08
NO174302C (no) 1994-04-13
PT78484B (fr) 1986-05-22
DE3486216T2 (de) 1994-02-17
EP0123228A3 (en) 1987-03-25
DE3486491T2 (de) 2003-01-16
JPH07143886A (ja) 1995-06-06
DK204584A (da) 1984-10-26
EP0561137A1 (en) 1993-09-22
FI841524A0 (fi) 1984-04-16
FI87799C (fi) 1993-02-25
US6642029B1 (en) 2003-11-04
DK204584D0 (da) 1984-04-24
JP2530424B2 (ja) 1996-09-04
ES531855A0 (es) 1985-05-16
EP0561137B1 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
NO841613L (no) Fremgangsmaate for produksjon av en human-insulinliknende vekstfaktor, samt dna-sammensetning for fremgangsmaatens utfoerelse
ATE318917T1 (de) Verfahren zur bakteriellen herstellung von heterologen polypeptiden mit disulfidbrücke
AU2443488A (en) Dna-molecules coding for fmdh control regions and structured gene for a protein having fmdh-activity and their uses
NO180381C (no) DNA-konstruksjoner inneholdende en Kluyveromyces alfa-faktor ledersekvens for utskillelse av heterologe polypeptider, ekspresjonsvektor og fremgangsmåte til fremstilling av et heterologt polypeptid i gjær
EP0494702A3 (en) Production of factor xiiia by gene technology
DE59410401D1 (de) VERFAHREN ZUR HERSTELLUNG REKOMBINANTER PilC-PROTEINE
EE03074B1 (et) Rekombinantsed eukarüootsed rakud, nende saamiseks vajalikud DNA järjestused, meetod eukarüootsete rakkude konstrueerimiseks ja sekreteeritavate valkude ning biomassi tootmismeetod
EP0266057A3 (en) Plasmid containing an eucaryotic secretory signal sequence and process for secreting encoded proteins
EP0171000A3 (en) Process for producing heterologous matured protein or peptide
ATE91717T1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
EP0282512A4 (en) STABILIZATION OF MESSENGER RNA IN ANIMAL CELLS.
ATE122097T1 (de) Expressionsvektor und verfahren zur regulierbaren herstellung von proteinen in eukaryonten.
MacKay et al. Methods of regulating protein glycosylation.